Kittelmann M, Klein T, Kragl U, Wandrey C, Ghisalba O
CIBA-GEIGY Limited, Pharmaceutical Division, Basel, Switzerland.
Ann N Y Acad Sci. 1992 Nov 30;672:444-50. doi: 10.1111/j.1749-6632.1992.tb32711.x.
Using Escherichia coli K-235 as a production strain in a fed-batch fermentation process with an optimized sorbitol/yeast extract medium, we were able to produce 640 U of CMP-Neu5Ac synthetase in 10 l scale (64 U/l) and 9200 U (total enzyme) in 200 l scale (390 U/kg wet weight). By simple one-step purification procedures, enzyme preparations were obtained that could be used efficiently for the synthesis of CMP-Neu5Ac from CTP and Neu5Ac with over 90% yield, from Neu5Ac, CMP, and ATP or phosphoenolpyruvate by in situ generation of CTP, and from CTP, pyruvate, and ManNAc or GlcNAc by in situ generation of Neu5Ac.
在补料分批发酵过程中,使用大肠杆菌K-235作为生产菌株,采用优化的山梨醇/酵母提取物培养基,我们能够在10升规模下生产640 U的CMP-唾液酸合成酶(64 U/升),在200升规模下生产9200 U(总酶量)(390 U/千克湿重)。通过简单的一步纯化程序,获得了酶制剂,该酶制剂可有效地用于从CTP和唾液酸合成CMP-唾液酸,产率超过90%;通过原位生成CTP,从唾液酸、CMP和ATP或磷酸烯醇丙酮酸合成CMP-唾液酸;通过原位生成唾液酸,从CTP、丙酮酸和甘露糖胺或N-乙酰葡糖胺合成CMP-唾液酸。